Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

Autor: Díez-Campelo, María ^*, López-Cadenas, Félix, Xicoy, Blanca, Lumbreras, Eva, González, Teresa, del Rey González, Mónica, Sánchez-García, Joaquín, Coll Jordà, Rosa, Slama, Bohrane, Hernández-Rivas, Jose-Ángel, Thepot, Sylvain, Bernal, Teresa, Guerci-Bresler, Agnès, Bargay, Joan, Amigo, María Luz, Preudhomme, Claude, Fenwarth, Laurene, Platzbecker, Uwe, Götze, Katharina S, Arar, Ali, Toribio, Sofía, Del Cañizo, Consuelo, Hernández-Rivas, Jesús María, Fenaux, Pierre

Publikováno v: In The Lancet Haematology September 2024 11(9):e659-e670

Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study

Autor: Stojkov, Igor, Conrads-Frank, Annette, Rochau, Ursula, Arvandi, Marjan, Koinig, Karin A., Schomaker, Michael, Mittelman, Moshe, Fenaux, Pierre, Bowen, David, Sanz, Guillermo F., Malcovati, Luca, Langemeijer, Saskia, Germing, Ulrich, Madry, Krzysztof, Guerci-Bresler, Agnès, Culligan, Dominic J., Kotsianidis, Ioannis, Sanhes, Laurence, Mills, Juliet, Puntscher, Sibylle, Schmid, Daniela, van Marrewijk, Corine, Smith, Alexandra, Efficace, Fabio, de Witte, Theo, Stauder, Reinhard, Siebert, Uwe

Publikováno v: In Blood Advances 27 June 2023 7(12):2772-2783

Clinical outcomes in patients in any phase of CML treated with ponatinib in France—Data from the TOPASE observational study.

Autor: Huguet, F.^1,2 (AUTHOR), Guerci‐Bresler, A.^2,3 (AUTHOR), Roth‐Guepin, G.^2,3 (AUTHOR), Cayssials, E.^2,4,5 (AUTHOR), Slama, B.⁶ (AUTHOR), Santagostino, A.⁷ (AUTHOR), Penot, A.^2,8 (AUTHOR), Quittet, P.^2,9 (AUTHOR), Cony‐Makhoul, P.^2,6 (AUTHOR), Saad, A.⁷ (AUTHOR), Bastie, J. N.¹⁰ (AUTHOR), Hacini, M.¹¹ (AUTHOR), Coiteux, V.^2,12 (AUTHOR), Uzunov, M.^2,13 (AUTHOR), Roy, L.^2,14 (AUTHOR), Le Clech, L.¹⁵ (AUTHOR), Berger, M.^2,16,17 (AUTHOR), Agneray, A. M.¹⁸ (AUTHOR) aagneray@incyte.com, Messas, E.¹⁹ (AUTHOR), Etienne, G.^2,20 (AUTHOR)

Publikováno v: British Journal of Haematology. Nov2024, p1. 10p. 3 Illustrations.

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

Autor: Stéphanie Dulucq, Franck E. Nicolini, Delphine Rea, Pascale Cony-Makhoul, Aude Charbonnier, Martine Escoffre-Barbe, Valérie Coiteux, Pascal Lenain, Françoise Rigal-Huguet, Jixing Liu, Agnès Guerci-Bresler, Laurence Legros, Jean-Christophe Ianotto, Martine Gardembas, Pascal Turlure, Viviane Dubruille, Philippe Rousselot, Juliana Martiniuc, Henry Jardel, Hyacinthe Johnson-Ansah, Bertrand Joly, Tawfiq Henni, Emilie Cayssials, Patricia Zunic, Marc G. Berger, Bruno Villemagne, Fanny Robbesyn, Stephane Morisset, François-Xavier Mahon, Gabriel Etienne

Publikováno v: Haematologica, Vol 107, Iss 12 (2022)

Discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia is feasible in clinical practice based on recently published international recommendations. Nevertheless, factors predictive of molecular recurrence have not been

Externí odkaz: https://doaj.org/article/28263e36eb3a4f589724f3b48b82115e

Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count

Autor: Marion Divoux, Alexia Plocque, Margaux Sevin, Laurent Voillat, Pierre Feugier, Agnès Guerci‐Bresler, Francois Girodon, Julien Broséus

Publikováno v: Clinical Case Reports, Vol 8, Iss 9, Pp 1774-1780 (2020)

Abstract Lenalidomide is efficient in reducing red blood cell transfusion dependency and markedly lowering platelet counts in MDS/MPN‐RS‐T in the context of major platelet counts.

Externí odkaz: https://doaj.org/article/4eb955fadf304ab59a650483cda4cf8a